USF-LVHN SELECT
An immunoinformatics assessment of the cancer testis antigen, DDX53, as a potential early esophageal cancer antigen.
Publication/Presentation Date
1-1-2023
Abstract
T-lymphocytes have been implicated in facilitating a pro-inflammatory, pro-tumorigenic microenvironment that worsens prognosis for esophageal carcinoma (ESCA). In this study, we identified tumor resident, T-cell receptor (TCR) complementarity determining region-3 (CDR3) amino acid sequences and employed an algorithm particularly suited to the big data setting to evaluate TCR CDR3-cancer testis antigen (CTA) chemical complementarities. Chemical complementarity of the ESCA TCR CDR3s and the cancer testis antigen DDX53 represented a disease-free survival (DFS) distinction, whereby the upper fiftieth percentile complementarity group correlated with worse DFS. The high TCR CDR3-DDX53 complementarity group also represented a greater proportion of tumor samples lacking DDX53 expression. These data and analyses raise the question of whether the TCR CDR3-DDX53 chemical complementarity assessment detected an ESCA immune response that selected for DDX53-negative cells?
Volume
10
First Page
59
Last Page
66
ISSN
2331-4737
Published In/Presented At
Cheng, P., Cios, K. J., Varkhedi, M., Barker, V. R., Yeagley, M., Chobrutskiy, A., Chobrutskiy, B. I., & Blanck, G. (2023). An immunoinformatics assessment of the cancer testis antigen, DDX53, as a potential early esophageal cancer antigen. Oncoscience, 10, 59–66. https://doi.org/10.18632/oncoscience.590
Disciplines
Medical Education | Medicine and Health Sciences
PubMedID
37953875
Department(s)
USF-LVHN SELECT Program, USF-LVHN SELECT Program Students
Document Type
Article